(Q27667652)

ChEBI release 2020-05-28

1 reference

10

Karl-Peter Hopfner

Karl-Peter

Hopfner

1 reference

19 October 2023

Silke Metz

1

Silke

Metz

1 reference

19 October 2023

Alexander K Haas

2

Alexander K

Haas

1 reference

19 October 2023

Karin Daub

3

Karin

Daub

1 reference

19 October 2023

Rebecca Croasdale

4

Rebecca

Croasdale

1 reference

19 October 2023

Jan Stracke

5

Jan

Stracke

1 reference

19 October 2023

Wilma Lau

6

Wilma

Lau

1 reference

19 October 2023

Guy Georges

7

Guy

Georges

1 reference

19 October 2023

Hans-Peter Josel

8

Hans-Peter

Josel

1 reference

19 October 2023

Sebastian Dziadek

9

Sebastian

Dziadek

1 reference

19 October 2023

Alfred Lammens

11

Alfred

Lammens

1 reference

19 October 2023

Werner Scheuer

12

Werner

Scheuer

1 reference

19 October 2023

Eike Hoffmann

13

Eike

Hoffmann

1 reference

19 October 2023

Olaf Mundigl

14

Olaf

Mundigl

1 reference

19 October 2023

Ulrich Brinkmann

15

Ulrich

Brinkmann

1 reference

Proceedings of the National Academy of Sciences of the United States of America

19 October 2023

language of work or name

English

0 references

publication date

17 May 2011

0 references

published in

0 references

volume

108

0 references

issue

20

0 references

page(s)

8194-9

0 references

cites work

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Bispecific antibodies for cancer immunotherapy: Current perspectives

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Catumaxomab: clinical development and future directions

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Strategies and challenges for the next generation of therapeutic antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Radioimmunotherapy of lymphoma: Bexxar and Zevalin

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

The type 1 insulin-like growth factor receptor pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Cancer Imaging and Therapy with Bispecific Antibody Pretargeting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Arming antibodies: prospects and challenges for immunoconjugates

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Fab antibody fragments: some applications in clinical toxicology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Immunotoxins in cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

The digoxigenin (DIG) system for non-radioactive labelling and detection of nucleic acids--an overview.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

The digoxigenin:anti-digoxigenin (DIG) technology--a survey on the concept and realization of a novel bioanalytical indicator system

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Non-radioactive labeling and detection of nucleic acids. II. Optimization of the digoxigenin system.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Non-radioactive labeling and detection of nucleic acids. I. A novel DNA labeling and detection system based on digoxigenin: anti-digoxigenin ELISA principle (digoxigenin system).

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Design and production of novel tetravalent bispecific antibodies

2 June 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1018565108

Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1018565108

Short-hairpin-RNA-mediated silencing of fucosyltransferase 8 in Chinese-hamster ovary cells for the production of antibodies with enhanced antibody immune effector function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1018565108

Chemie der herzaktiven Glykoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1018565108

Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3100918

Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21536919

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFalpha, anti-IL-1alpha/beta and IL-1Ra

1 reference

https://pubmed.ncbi.nlm.nih.gov/21536919

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3

1 reference

https://pubmed.ncbi.nlm.nih.gov/21536919

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1073/PNAS.1018565108

1 reference

ADS bibcode

2011PNAS..108.8194M

0 references

1 reference

1 reference

1 reference